{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:00:07Z","timestamp":1785243607284,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81071083"],"award-info":[{"award-number":["81071083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Science and Technology Commission","award":["D101107047810001"],"award-info":[{"award-number":["D101107047810001"]}]}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.psychres.2016.01.031","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T19:10:25Z","timestamp":1452971425000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review"],"prefix":"10.1016","volume":"237","author":[{"given":"Qi-Jing","family":"Bo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2016.01.031_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/070674370104600906","article-title":"Antipsychotic drugs and obesity: Is prolactin involved?","volume":"46","author":"Baptista","year":"2001","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2016.01.031_bib3","first-page":"CD006617","article-title":"Aripiprazole versus typicals for schizophrenia","volume":"16","author":"Bhattacharjee","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2016.01.031_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/09513590902770172","article-title":"Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome","volume":"25","author":"Billa","year":"2009","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.psychres.2016.01.031_bib5","first-page":"1075","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"44","author":"Biller","year":"1999","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.psychres.2016.01.031_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psychres.2016.01.031_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.schres.2009.07.012","article-title":"Schizophrenia and breast cancer incidence: a systematic review of clinical studies","volume":"114","author":"Bushe","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2016.01.031_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2013.13060771","article-title":"Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?","volume":"170","author":"Correll","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib13","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.09m05274yel","article-title":"The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis","volume":"71","author":"Ehret","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Br. Med. J."},{"key":"10.1016\/j.psychres.2016.01.031_bib15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psychres.2016.01.031_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.psychres.2016.01.031_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/appi.psy.50.4.317","article-title":"Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia","volume":"50","author":"Hoffer","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psychres.2016.01.031_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust. N.Z J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder","volume":"170","author":"Jarskog","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-0031-1291175","article-title":"Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride","volume":"45","author":"Kim","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","article-title":"Osteoporosis and fracture risk in people with schizophrenia","volume":"25","author":"Kishimoto","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12020-014-0428-2","article-title":"The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study","volume":"49","author":"Krysiak","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.psychres.2016.01.031_bib24","unstructured":"Leandro, G. 2008. Meta-analysis in Medical Research: The Handbook for the Understanding and Practice of Meta-analysis. Wiley.com. Available from: \u3008http:\/\/www.books.google.com\u3009 (accessed May 2015)."},{"issue":"2 Suppl","key":"10.1016\/j.psychres.2016.01.031_bib25","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2016.01.031_bib28","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2016.01.031_bib29","first-page":"54","article-title":"Effect of metformin on antipsychotic drug-induced galactorrhea-amenorrhea syndrome","volume":"20","author":"Liang","year":"2013","journal-title":"China Mod. Med."},{"key":"10.1016\/j.psychres.2016.01.031_bib30","doi-asserted-by":"crossref","first-page":"e1140","DOI":"10.4088\/JCP.14cr09133","article-title":"Metformin for weight loss and control in patients with mood disorder","volume":"75","author":"Linneke","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib31","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.psychres.2016.01.031_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00404-011-1963-1","article-title":"Schizophrenia and Stein-Leventhal syndrome: comorbidity features","volume":"284","author":"Matevosyan","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.psychres.2016.01.031_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/7854_2010_45","article-title":"Antipsychotics and metabolics in the post-CATIE era","volume":"4","author":"Meyer","year":"2010","journal-title":"Curr. Top. Bevav. Neurosci."},{"key":"10.1016\/j.psychres.2016.01.031_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.psychres.2016.01.031_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert. Opin. Drug. Saf."},{"key":"10.1016\/j.psychres.2016.01.031_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstrom","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/0092623X.2011.606883","article-title":"Strategies for the treatment of antipsychotic-induced sexual dysfunction and\/or hyperprolactinemia among patients of the schizophrenia spectrum: a review","volume":"38","author":"Nunes","year":"2012","journal-title":"J. Sex. Marital. Ther."},{"key":"10.1016\/j.psychres.2016.01.031_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O'Keane","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.1.05844","article-title":"Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome","volume":"184","author":"Ortega-Gonzalez","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.psychres.2016.01.031_bib40","first-page":"635","article-title":"Interpreting and understanding meta-analysis graphs \u2013 a practical guide","volume":"35","author":"Ried","year":"2006","journal-title":"Aust. Fam. Phys."},{"key":"10.1016\/j.psychres.2016.01.031_bib41","first-page":"408","article-title":"Preliminary observation of the metformin in efficacy for hyperprolactinemia induced by antipsychotics","volume":"23","author":"Shi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib42","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1176\/appi.ajp.2012.12050591","article-title":"Metformin as a treatment for antipsychotic drug side effects: special focus on women with schizophrenia","volume":"169","author":"Smith","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy","volume":"43","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.psychres.2016.01.031_bib45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1176\/appi.ajp.2009.09030358","article-title":"Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial","volume":"167","author":"Wang","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.01.031_bib47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00004714-199908000-00018","article-title":"Herbal medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea","volume":"19","author":"Yamada","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","article-title":"A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia","volume":"28","author":"Yuan","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.01.031_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.schres.2014.06.003","article-title":"Polycystic ovaries is a disproportionate signal in pharmacovigilance data mining of second generation antipsychotics","volume":"158","author":"Yum","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811630083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517811630083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:18:44Z","timestamp":1567538324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016517811630083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":49,"alternative-id":["S016517811630083X"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2016.01.031","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2016.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}